Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


21.05.2018

4 BJU Int
1 BMC Cancer
1 Br J Cancer
1 Br J Radiol
1 Cancer Imaging
1 Cancer Lett
2 Cancer Res
1 Clin Cancer Res
1 Int J Oncol
2 Int J Urol
1 J Urol
2 Lancet Oncol
1 N Engl J Med
4 Nat Rev Urol
1 Oncogene
2 Prostate
1 Urology


   Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BJU Int

  1. HAJILI T, Ohlmann CH, Linxweiler J, Niklas C, et al
    Radical prostatectomy in T4 prostate cancer after inductive androgen deprivation: Results of a single-institution series with long-term follow up.
    BJU Int. 2018 May 17. doi: 10.1111/bju.14393.
    PubMed     Text format     Abstract available

  2. ISHIOKA J, Matsuoka Y, Uehara S, Yasuda Y, et al
    Computer-aided diagnosis of prostate cancer on magnetic resonance imaging using a convolutional neural network algorithm.
    BJU Int. 2018 May 17. doi: 10.1111/bju.14397.
    PubMed     Text format     Abstract available

  3. ZHAO J, Sun G, Liao B, Zhang X, et al
    Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone-metastatic prostate cancer.
    BJU Int. 2018 May 17. doi: 10.1111/bju.14398.
    PubMed     Text format     Abstract available

  4. GANDAGLIA G, van den Bergh RCN, Tilki D, Fossati N, et al
    How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator.
    BJU Int. 2018 May 17. doi: 10.1111/bju.14391.
    PubMed     Text format     Abstract available


    BMC Cancer

  5. PASQUIER D, Bogart E, Bonodeau F, Lacornerie T, et al
    BioPro-RCMI-1505 trial: multicenter study evaluating the use of a biodegradable balloon for the treatment of intermediate risk prostate cancer by intensity modulated radiotherapy; study protocol.
    BMC Cancer. 2018;18:566.
    PubMed     Text format     Abstract available


    Br J Cancer

  6. GAO F, Alwhaibi A, Artham S, Verma A, et al
    Endothelial Akt1 loss promotes prostate cancer metastasis via beta-catenin-regulated tight-junction protein turnover.
    Br J Cancer. 2018 May 14. pii: 10.1038/s41416-018-0110.
    PubMed     Text format     Abstract available


    Br J Radiol

  7. KULKARNI HR, Singh A, Langbein T, Schuchardt C, et al
    Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.
    Br J Radiol. 2018 May 15:20180308. doi: 10.1259/bjr.20180308.
    PubMed     Text format     Abstract available


    Cancer Imaging

  8. DAMJANOVIC J, Janssen JC, Furth C, Diederichs G, et al
    (68) Ga-PSMA-PET/CT for the evaluation of pulmonary metastases and opacities in patients with prostate cancer.
    Cancer Imaging. 2018;18:20.
    PubMed     Text format     Abstract available


    Cancer Lett

  9. KANWAL R, Shukla S, Walker E, Gupta S, et al
    Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics.
    Cancer Lett. 2018 May 15. pii: S0304-3835(18)30339.
    PubMed     Text format     Abstract available


    Cancer Res

  10. LU X, Pan X, Wu CJ, Zhao D, et al
    An in vivo screen identifies PYGO2 as a driver for metastatic prostate cancer.
    Cancer Res. 2018 May 16. pii: 0008-5472.CAN-17-3564.
    PubMed     Text format     Abstract available

  11. MOSES MA, Kim YS, Rivera-Marquez GM, Oshima N, et al
    Targeting the Hsp40/Hsp70 chaperone axis as a novel strategy to treat castration-resistant prostate cancer.
    Cancer Res. 2018 May 15. pii: 0008-5472.CAN-17-3728.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  12. ALSHALALFA M, Karnes RJ, Sharma V, Choeurng V, et al
    Development and validation of a prostate cancer genomic signature that predicts early ADT treatment response following radical prostatectomy.
    Clin Cancer Res. 2018 May 14. pii: 1078-0432.CCR-17-2745.
    PubMed     Text format     Abstract available


    Int J Oncol

  13. OAK C, Khalifa AO, Isali I, Bhaskaran N, et al
    Diosmetin suppresses human prostate cancer cell proliferation through the induction of apoptosis and cell cycle arrest.
    Int J Oncol. 2018 May 16. doi: 10.3892/ijo.2018.4407.
    PubMed     Text format     Abstract available


    Int J Urol

  14. CHEN PY, Chiang PH, Liu YY, Chuang YC, et al
    Primary whole-gland ablation for localized prostate cancer with high-intensity focused ultrasound: The important predictors of biochemical recurrence.
    Int J Urol. 2018 May 13. doi: 10.1111/iju.13581.
    PubMed     Text format     Abstract available

  15. YANO A, Arai Y, Kitayama S, Otsuka Y, et al
    Effect of zoledronic acid dosing every 3 months in patients with prostate cancer with skeletal metastases: A multicenter prospective exploratory study with matched historical controls.
    Int J Urol. 2018 May 14. doi: 10.1111/iju.13703.
    PubMed     Text format    


    J Urol

  16. AMINSHARIFI A, Howard L, Wu Y, De Hoedt A, et al
    Prostate-specific antigen density as a predictor of clinically significant prostate cancer when the PSA level is in the diagnostic "grey-zone": Defining the optimum cut-point stratified by race and body mass index.
    J Urol. 2018 May 11. pii: S0022-5347(18)43126-6. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


    Lancet Oncol

  17. HOFMAN MS, Violet J, Hicks RJ, Ferdinandus J, et al
    [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
    Lancet Oncol. 2018 May 7. pii: S1470-2045(18)30198.
    PubMed     Text format     Abstract available

  18. PAGANELLI G, De Giorgi U
    [(177)Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet?
    Lancet Oncol. 2018 May 7. pii: S1470-2045(18)30268.
    PubMed     Text format    


    N Engl J Med

  19. SMITH TJ, Loprinzi CL, Deville C
    Oxybutynin for Hot Flashes Due to Androgen Deprivation in Men.
    N Engl J Med. 2018;378:1745-1746.
    PubMed     Text format    


    Nat Rev Urol

  20. PIGNOT G, Maillet D, Gross E, Barthelemy P, et al
    Systemic treatments for high-risk localized prostate cancer.
    Nat Rev Urol. 2018 May 15. pii: 10.1038/s41585-018-0017.
    PubMed     Text format     Abstract available

  21. CAPIOD T, Barry Delongchamps N, Pigat N, Souberbielle JC, et al
    Do dietary calcium and vitamin D matter in men with prostate cancer?
    Nat Rev Urol. 2018 May 15. pii: 10.1038/s41585-018-0015.
    PubMed     Text format     Abstract available

  22. YANG W, Freeman MR, Kyprianou N
    Personalization of prostate cancer therapy through phosphoproteomics.
    Nat Rev Urol. 2018 May 11. pii: 10.1038/s41585-018-0014.
    PubMed     Text format     Abstract available

  23. BERISH RB, Ali AN, Telmer PG, Ronald JA, et al
    Translational models of prostate cancer bone metastasis.
    Nat Rev Urol. 2018 May 16. pii: 10.1038/s41585-018-0020.
    PubMed     Text format     Abstract available


    Oncogene

  24. GARG R, Blando JM, Perez CJ, Lal P, et al
    COX-2 mediates pro-tumorigenic effects of PKCepsilon in prostate cancer.
    Oncogene. 2018 May 16. pii: 10.1038/s41388-018-0318.
    PubMed     Text format     Abstract available


    Prostate

  25. AL SALEH HA, Haas-Neill S, Al-Hashimi A, Kapoor A, et al
    Thrombotic characteristics of extracellular vesicles derived from prostate cancer cells.
    Prostate. 2018 May 15. doi: 10.1002/pros.23653.
    PubMed     Text format     Abstract available

  26. MIYAHIRA AK, Soule HR
    The 24th Annual Prostate Cancer Foundation scientific retreat report.
    Prostate. 2018 May 15. doi: 10.1002/pros.23651.
    PubMed     Text format     Abstract available


    Urology

  27. BUELENS S, Van Praet C, Poelaert F, Van Huele A, et al
    Prospective, Randomized Controlled Trial Exploring the Effect of TachoSil(R) on Lymphocele Formation after Extended Pelvic Lymph Node Dissection in Prostate Cancer.
    Urology. 2018 May 15. pii: S0090-4295(18)30463.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: